Anya Biopharm, Inc.

As of June 30, 2026, Anya Biopharm, Inc. carries a market capitalization of 1.26B, placing it among publicly traded companies globally. Its enterprise value stands at 947.60M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Anya Biopharm, Inc. has 49.10M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Anya Biopharm, Inc. maintains a current ratio of 67.66, meaning it holds 67.7x the short-term assets needed to cover near-term liabilities.

As of the close on October 22, 2026, Anya Biopharm, Inc.'s stock has declined approximately 36.35% over the past 52 weeks. The 50-day moving average sits at 32.54, while the 200-day moving average is 32.60.

As of June 30, 2026, Anya Biopharm, Inc. holds 317.84M in cash and equivalents against 3.52M in total debt, resulting in a net debt position of -158.33M. Total book value stands at 349.34M, with working capital of 330.45M providing operational flexibility.